KR102601972B1 - 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체 - Google Patents

중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체 Download PDF

Info

Publication number
KR102601972B1
KR102601972B1 KR1020177025290A KR20177025290A KR102601972B1 KR 102601972 B1 KR102601972 B1 KR 102601972B1 KR 1020177025290 A KR1020177025290 A KR 1020177025290A KR 20177025290 A KR20177025290 A KR 20177025290A KR 102601972 B1 KR102601972 B1 KR 102601972B1
Authority
KR
South Korea
Prior art keywords
compound
isochroman
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177025290A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129730A (ko
Inventor
링홍 시에
필립 글린 존스
케리 엘 스페어
노엘 애론 포웰
탈린 지 하나니아
바딤 알렉산드로브
Original Assignee
선오비온 파마슈티컬스 인코포레이티드
피지아이 드럭 디스커버리 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선오비온 파마슈티컬스 인코포레이티드, 피지아이 드럭 디스커버리 엘엘시 filed Critical 선오비온 파마슈티컬스 인코포레이티드
Publication of KR20170129730A publication Critical patent/KR20170129730A/ko
Application granted granted Critical
Publication of KR102601972B1 publication Critical patent/KR102601972B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177025290A 2015-02-11 2016-02-11 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체 Active KR102601972B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
US62/115,064 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Publications (2)

Publication Number Publication Date
KR20170129730A KR20170129730A (ko) 2017-11-27
KR102601972B1 true KR102601972B1 (ko) 2023-11-13

Family

ID=55456908

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025290A Active KR102601972B1 (ko) 2015-02-11 2016-02-11 중추 신경계 질환을 치료하기 위한 1-헤테로사이클릴 이소크로만일 화합물 및 유사체

Country Status (22)

Country Link
US (4) US9856238B2 (cg-RX-API-DMAC7.html)
EP (2) EP4046995B1 (cg-RX-API-DMAC7.html)
JP (3) JP6657241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102601972B1 (cg-RX-API-DMAC7.html)
CN (2) CN111925360B (cg-RX-API-DMAC7.html)
AU (1) AU2016219253C1 (cg-RX-API-DMAC7.html)
CA (1) CA2976095C (cg-RX-API-DMAC7.html)
CY (1) CY1125198T1 (cg-RX-API-DMAC7.html)
DK (1) DK3256466T3 (cg-RX-API-DMAC7.html)
EA (1) EA201791804A1 (cg-RX-API-DMAC7.html)
ES (2) ES2967643T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058698T2 (cg-RX-API-DMAC7.html)
IL (1) IL253914B (cg-RX-API-DMAC7.html)
MX (2) MX392664B (cg-RX-API-DMAC7.html)
MY (1) MY188160A (cg-RX-API-DMAC7.html)
NZ (1) NZ735011A (cg-RX-API-DMAC7.html)
PH (1) PH12017501422A1 (cg-RX-API-DMAC7.html)
PL (1) PL3256466T3 (cg-RX-API-DMAC7.html)
PT (1) PT3256466T (cg-RX-API-DMAC7.html)
SG (2) SG10201806809QA (cg-RX-API-DMAC7.html)
UA (1) UA122222C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016130796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс
US9758529B2 (en) * 2015-02-11 2017-09-12 Sunovion Pharmaceuticals Inc. Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465186A1 (en) * 2001-11-08 2003-05-15 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN Registry, CAS 1050749-85-3(2008.9.21.)*

Also Published As

Publication number Publication date
CN111925360A (zh) 2020-11-13
US11192885B2 (en) 2021-12-07
US20180093974A1 (en) 2018-04-05
KR20170129730A (ko) 2017-11-27
MX392664B (es) 2025-03-24
PH12017501422A1 (en) 2018-03-19
DK3256466T3 (da) 2022-05-02
PT3256466T (pt) 2022-05-10
AU2016219253C1 (en) 2022-12-08
US20170001987A1 (en) 2017-01-05
JP2018505205A (ja) 2018-02-22
AU2016219253A1 (en) 2017-09-21
ES2967643T3 (es) 2024-05-03
WO2016130796A1 (en) 2016-08-18
HUE058698T2 (hu) 2022-09-28
EP4046995C0 (en) 2023-09-13
UA122222C2 (uk) 2020-10-12
ES2911910T3 (es) 2022-05-23
MX371404B (es) 2020-01-29
EP3256466B9 (en) 2022-07-27
BR112017017354A2 (pt) 2018-04-10
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
EP3256466A1 (en) 2017-12-20
CY1125198T1 (el) 2024-12-13
CN107531674A (zh) 2018-01-02
JP6657241B2 (ja) 2020-03-04
EP3256466B1 (en) 2022-04-06
CA2976095A1 (en) 2016-08-18
MY188160A (en) 2021-11-24
MX2017010363A (es) 2018-05-04
SG10201806809QA (en) 2018-09-27
IL253914B (en) 2021-09-30
CN111925360B (zh) 2024-03-22
US9856238B2 (en) 2018-01-02
CN107531674B (zh) 2020-07-31
EP4046995B1 (en) 2023-09-13
EA201791804A1 (ru) 2018-02-28
ES2911910T9 (es) 2022-08-12
NZ735011A (en) 2023-07-28
US20220185799A1 (en) 2022-06-16
JP2022065050A (ja) 2022-04-26
US20190389845A1 (en) 2019-12-26
JP7023994B2 (ja) 2022-02-22
CA2976095C (en) 2023-10-17
PL3256466T3 (pl) 2022-05-23
AU2016219253B2 (en) 2020-10-01
US10336732B2 (en) 2019-07-02
IL253914A0 (en) 2017-10-31
EP4046995A1 (en) 2022-08-24
MX2020001157A (es) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7023994B2 (ja) Cns疾患を治療するための1-複素環イソクロマニル化合物およびアナログ
KR102623321B1 (ko) 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
EP3661929B1 (en) Isochroman compounds and uses thereof
JP2023545081A (ja) 嚢胞性線維症膜コンダクタンス制御因子モジュレーター
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40042391A (en) 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders
EA046724B1 (ru) Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс
HK1241876B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
BR112017017354B1 (pt) Composto e seu uso, composição, processo para preparar um composto

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221223

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230912

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231109

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration